Item 8.01 Other Items.

On March 30, 2020, MyoKardia, Inc. issued a press release titled "MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients." A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits




(d) Exhibits.

 Exhibit
   No.           Description

   99.1            Press Release, dated March 30, 2020.

   104           Cover Page Interactive Data File (embedded within the Inline XBRL
                 document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses